ENVB vs. ZVSA, BFRI, XBIO, ENSC, NEXI, YMTX, KA, PULM, GTBP, and SNGX
Should you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include ZyVersa Therapeutics (ZVSA), Biofrontera (BFRI), Xenetic Biosciences (XBIO), Ensysce Biosciences (ENSC), NexImmune (NEXI), Yumanity Therapeutics (YMTX), Kineta (KA), Pulmatrix (PULM), GT Biopharma (GTBP), and Soligenix (SNGX). These companies are all part of the "pharmaceutical preparations" industry.
ZyVersa Therapeutics (NASDAQ:ZVSA) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
ZyVersa Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 1,443.41%. Enveric Biosciences has a consensus target price of $10.00, indicating a potential upside of 880.39%. Given Enveric Biosciences' higher possible upside, equities research analysts plainly believe ZyVersa Therapeutics is more favorable than Enveric Biosciences.
Enveric Biosciences' return on equity of -233.62% beat ZyVersa Therapeutics' return on equity.
Enveric Biosciences received 2 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 55.56% of users gave Enveric Biosciences an outperform vote.
3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 0.7% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, ZyVersa Therapeutics had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 9 mentions for ZyVersa Therapeutics and 6 mentions for Enveric Biosciences. ZyVersa Therapeutics' average media sentiment score of 0.87 beat Enveric Biosciences' score of 0.56 indicating that Enveric Biosciences is being referred to more favorably in the news media.
ZyVersa Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Summary
Enveric Biosciences beats ZyVersa Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Enveric Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Enveric Biosciences Competitors List
Related Companies and Tools